Radiopharmaceuticals Market Size, Share, & Growth Report By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine), By Application (Diagnostic Applications, Therapeutic Applications), By Procedural Volume Assessment (Diagnostic Procedures, Therapeutic Procedures), By Source (Nuclear Reactors, Cyclotrons), By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, Others), and By Region – Global and Regional Industry Overview, Market Intelligence, Premium Insights, Complete Analysis, Historical Data, and Forecasts 2022 – 2028
The global radiopharmaceuticals market size was worth USD 4.6 billion in 2021 and is estimated to grow to USD 8.3 billion by 2028, with a CAGR of approximately 8.80 percent over the forecast years.
Radiopharmaceuticals are unique mixtures of radioisotopes utilized in therapeutic settings for treatment and diagnostics. A radio pharmacist, a physician with expertise in nuclear medicine, is responsible for dispensing these medications. They are either swallowed as pills or injected directly into the patient’s vein or body cavity. When they arrive at the desired place, they discharge radioactive substances to eliminate the tumor cells. As a result, radiopharmaceuticals are utilized to treat cancers that have progressed to the bones, including thyroid, lymphoma, brain, and others. The increasing incidence of malignant diseases brought on by an aging population and unhealthful eating habits are the leading causes of the expanding use of radiopharmaceuticals worldwide. Additionally, the market is being supported by the growing number of diagnostic centers. Further, the increasing number of oncologists who advocate disease-targeted cancer therapy, which employs medications to target particular proteins and genes involved in the growth of cancer cells, is helping to boost overall sales. Along with rising healthcare costs, other factors, such as radio-labeled peptides and monoclonal antibodies for identifying and treating malignant tumors, are boosting the market growth.
COVID-19 Impact on the Radiopharmaceuticals Market:
Due to the financial and resource cuts made during this phase, COVID-19 caused a setback in the market. The pandemic caused significant modifications in radiology departments’ clinical practices worldwide. The decline in market income was caused by a delay in the number of non-elective diagnostic procedures and treatment surgeries. In addition, academic medical facilities and universities were urged to stop conducting scientific research to increase the social distance effect. Reduced funding for these research and development projects also slowed the market’s expansion.
Radiopharmaceuticals Market Drivers:
The prevalence of numerous chronic diseases, including cancer, cardiovascular conditions, and others, has increased significantly, which has propelled the demand for radiopharmaceuticals. For example, around 17 million new instances of cancer were reported in 2018, according to a Research UK analysis. The desire for more precise diagnoses for better treatment has increased along with the prevalence of chronic illnesses. This has led to a rise in the widespread use of medical imaging, which uses radiopharmaceuticals as a tracer to find the body’s defective tissue. Additionally, since these medications help improve and reduce pain in treating chronic illnesses, future advancements in radiopharmaceuticals are anticipated to support the expansion of the radiopharmaceutical market throughout the projected year.
Radiopharmaceuticals Market: Restraints
High costs for research and development, a lack of adequate infrastructure, the short half-life of radiopharmaceuticals, expensive equipment, and a lack of knowledge in developing nations are all predicted to hinder market expansion. Additionally, hospital budget cuts, particularly during the pandemic, a lack of suitable infrastructure in low- and middle-income countries, an unfavorable reimbursement scenario, and technology penetration in developing economies are anticipated to pose challenges to the market during the forecast period.
The global radiopharmaceuticals market has been segmented into type, application, procedural volume assessment, source, and end user.
Based on type, the market is divided into diagnostic nuclear medicine and therapeutic nuclear medicine. Among these, the diagnostic nuclear medicine segment led the market in 2021 and is expected to maintain its dominance throughout the forecast period due to causes like practical cancer imaging for patients with different forms of cancer, new product introductions for the diagnosis of other illnesses, and rising procedure volumes globally. Besides, the therapeutic nuclear medicine category is anticipated to grow significantly. The comparative effectiveness of the treatments, the benefits of various treatment alternatives, and the rising interest in therapeutic radiopharmaceuticals by market participants who place a heavy emphasis on clinical trials can all be attributed to the increase.
Based on end users, the market is classified into hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and others. In 2021, hospitals dominated the global market. The increased procedural volume of nuclear imaging operations and the improved efficiency of handling these delicate items at hospitals and clinics are credited with the growth rate. Besides, the diagnostic center’s category is anticipated to grow significantly. The large volume of procedures performed at diagnostic centers across Europe and the rising number of diagnostic institutions are factors in this segment’s rapid expansion.
Radiopharmaceuticals Market: Regional Landscape
In 2021, North America dominated the market for radiopharmaceuticals because of the region’s robust healthcare infrastructure; it was a rising overweight population, a large patient population suffering from chronic diseases like cancer, coronary artery disease, and strokes, and increased research activity. Additionally, the rising incidence of cardiovascular diseases and cancer in the US fuels the market for radiopharmaceuticals. Due to an aging population and poor lifestyle decisions that have led to an increase in cancer and obesity cases, nuclear medicine sales have increased. The development of the nation’s radiopharmaceutical industry is anticipated to be boosted by using novel radioisotope manufacturing techniques to treat these ailments. According to the American Heart Association, cardiovascular disease claims 17.3 million lives yearly.
Some of the main competitors dominating the global radiopharmaceuticals market include- Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG, Bracco Imaging, Eczacýbaþý-Monrol Nuclear Products, Nordion, Advanced Accelerator Applications, NTP Radioisotopes, JSC Isotope, NorthStar Medical Radioisotopes, Eckert & Ziegler, Braun Melsungen AG, Smith & Nephew plc, Zimmer Biomet, Hanger Inc., and Otto Bock Healthcare GmBH.
Recent Developments
March 2021: The conclusion of a solid tumor series was announced by Aktis Oncology, a biotechnology company creating a novel class of targeted radiopharmaceuticals to treat various stable tumor cancer patients.
November 2020: Top Canadian radiopharmaceutical company Fusion Pharmaceuticals has partnered with Anglo-Swedish pharmaceutical behemoth AstraZeneca to market and develop next-generation alpha-emitting radiopharmaceuticals and combination therapies for cancer therapy.
Global Radiopharmaceuticals Market is segmented as follows:
Radiopharmaceuticals Market by Type
Diagnostic Nuclear Medicine
Therapeutic Nuclear Medicine
Radiopharmaceuticals Market by Application
Diagnostic Applications
Therapeutic Applications
Radiopharmaceuticals Market by Procedural Volume Assessment
Diagnostic Procedures
Therapeutic Procedures
Radiopharmaceuticals Market by Source
Nuclear Reactors
Cyclotrons
Radiopharmaceuticals Market by End User
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Cancer Research Institutes
Others
Radiopharmaceuticals Market by Region
North America
The U.S.
Canada
Mexico
Europe
France
The UK
Spain
Germany
Italy
Rest of Europe
Asia Pacific
China
Japan
India
New Zealand
Australia
South Korea
Southeast Asia
Rest of Southeast Asia
The Middle East & Africa
Saudi Arabia
UAE
Egypt
Kuwait
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Radiopharmaceuticals Market Report Scope
Report Attribute
Details
Market Size Value in 2022
USD 5 billion
Revenue Forecast in 2028
USD 8.3 billion
Growth Rate
CAGR of 4.5 % from 2022 to 2028
Base Year for Estimation
2021
Historical Data
2017 – 2021
Forecast Years
2022 – 2028
Quantitative Units
Revenue in USD million and CAGR from 2022 to 2028
Report Coverage
Revenue forecast, company ranking, Trends
competitive landscape, and growth factors
Segments Covered
Type, Application, Procedural Volume Assessment, Source, End User, and Region
Regional Scope
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG, Bracco Imaging, Eczacýbaþý-Monrol Nuclear Products, Nordion, Advanced Accelerator Applications, NTP Radioisotopes, JSC Isotope, NorthStar Medical Radioisotopes, Eckert & Ziegler, Braun Melsungen AG, Smith & Nephew plc, Zimmer Biomet, Hanger Inc., and Otto Bock Healthcare GmBH.
Table of Content
Radiopharmaceuticals Market Size, Share, Growth, and Forecast Report
1. Introduction
1.1. Report Description
1.1.1. Aim of the Report
1.1.2. Prospective Audience
1.1.3. Unique Selling Prepositions and Key Takeaways from the Report
1.2. Scope of the Research Study
1.3. Approach/Research Methodology
1.3.1. Secondary Research
1.3.2. Primary Research
1.3.3. Expert Panel Review
1.3.4. Market Data Breakdown and Data Triangulation
1.3.5. Research Approach for Market Size Estimation
1.3.5.1. Top-Down Approach
1.3.5.2. Bottom-Up Approach
1.3.6. Key Assumptions
1.4. Market Segmentation
1.4.1. Type
1.4.2. Application
1.4.3. Procedural Volume Assessment
1.4.4. Source
1.4.5. End User
2. Radiopharmaceuticals Market Overview
2.1. Introduction
2.2. Analysis by Type, 2016-2028 (US$ Billion)
2.3. Analysis by Application, 2016-2028 (US$ Billion)
2.4. Analysis by Procedural Volume Assessment, 2016-2028 (US$ Billion)
2.5. Analysis by Source, 2016-2028 (US$ Billion)
2.6. Analysis by End User, 2016-2028 (US$ Billion)
2.7. Market Analysis by Region, 2016-2028 (US$ Billion)
3. Radiopharmaceuticals Market Dynamics
3.1. Introduction
3.2. Growth Drivers
3.3. Growth Restraints
3.4. Growth Opportunities
3.5. Porter’s Five Forces Analysis
3.5.1. Threat of New Entrants
3.5.2. Bargaining Power of Buyers/Consumers
3.5.3. Bargaining Power of Suppliers
3.5.4. Threat of Substitute Types
3.5.5. Intensity of Competitive Rivalry
3.6. Attractiveness Analysis
3.6.1. Type
3.6.2. Application
3.6.3. Procedural Volume Assessment
3.6.4. Source
3.6.5. End User
3.6.6. Region
3.7. Value Chain Analysis
4. Radiopharmaceuticals Market Competition Analysis
4.1. Radiopharmaceuticals Market Share Analysis by Company, 2019 – 2021
4.1.1. Top 3 Players, 2019 – 2021
4.1.2. Top 6 Players, 2019 – 2021
4.2. Strategic Initiatives
4.2.1. New Products Launch
4.2.2. Mergers/Acquisitions
4.2.3. Agreement and Collaborations
4.2.4. Partnerships, Joint Ventures, Expansion, and Distribution
5. Global Radiopharmaceuticals Market Analysis by Type, Application, Procedural Volume Assessment, Source and End User, 2016-2028 (US$ Billion) 5.1. Type
5.1.1. Global Radiopharmaceuticals Market Share, by Type, 2021 and 2028
5.1.2. Global Radiopharmaceuticals Market Revenue, by Type, 2016-2028 (US$ Billion)
5.1.3. By Diagnostic Nuclear Medicine Market Analysis 2016-2028 (US$ Billion)
5.1.4. By Therapeutic Nuclear Medicine Market Analysis 2016-2028 (US$ Billion)
5.2. Application
5.2.1. Market Share, by Application, 2021 and 2028
5.2.2. Market Revenue, by Application, 2016-2028 (US$ Billion)
5.2.3. By Diagnostic Applications Market Analysis 2016-2028 (US$ Billion)
5.2.4. By Therapeutic Applications Market Analysis 2016-2028 (US$ Billion)
5.3. Procedural Volume Assessment
5.3.1. Market Share, by Procedural Volume Assessment, 2021 and 2028
5.3.2. Market Revenue, by Procedural Volume Assessment, 2016-2028 (US$ Billion)
5.3.3. By Diagnostic Procedures Market Analysis 2016-2028 (US$ Billion)
5.3.4. By Therapeutic Procedures Market Analysis 2016-2028 (US$ Billion)
5.4. Source
5.4.1. Market Share, by Source, 2021 and 2028
5.4.2. Market Revenue, by Source, 2016-2028 (US$ Billion)
5.4.3. By Nuclear Reactors Market Analysis 2016-2028 (US$ Billion)
5.4.4. By Cyclotrons Market Analysis 2016-2028 (US$ Billion)
5.5. End User
5.5.1. Market Share, by End User, 2021 and 2028
5.5.2. Market Revenue, by End User, 2016-2028 (US$ Billion)
5.5.3. By Hospitals Market Analysis 2016-2028 (US$ Billion)
5.5.4. By Ambulatory Surgical Centers Market Analysis 2016-2028 (US$ Billion)
5.5.5. By Diagnostic Centers Market Analysis 2016-2028 (US$ Billion)
5.5.6. By Cancer Research Institutes Market Analysis 2016-2028 (US$ Billion)
6. Global Radiopharmaceuticals Market Type Analysis by Region, 2016-2028 (US$ Billion)
6.1. Diagnostic Nuclear Medicine Market Analysis 2016-2028 (US$ Billion)
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East & Africa
6.2. Therapeutic Nuclear Medicine Market Analysis 2016-2028 (US$ Billion)
7. Global Radiopharmaceuticals Market Application Analysis by Region, 2016-2028 (US$ Billion)
7.1. Diagnostic Applications Market Analysis 2016-2028 (US$ Billion)
7.1.1. North America
7.1.2. Europe
7.1.3. Asia Pacific
7.1.4. Latin America
7.1.5. Middle East & Africa
7.2. Therapeutic Applications Market Analysis 2016-2028 (US$ Billion)
8. Global Radiopharmaceuticals Market Procedural Volume Assessment Analysis by Region, 2016-2028 (US$ Billion)
8.1. Diagnostic Procedures Market Analysis 2016-2028 (US$ Billion)
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Therapeutic Procedures Market Analysis 2016-2028 (US$ Billion)
9. Global Radiopharmaceuticals Market Source Analysis by Region, 2016-2028 (US$ Billion)
9.1. Nuclear Reactors Market Analysis 2016-2028 (US$ Billion)
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Latin America
9.1.5. Middle East & Africa
9.2. Cyclotrons Market Analysis 2016-2028 (US$ Billion)
10. Global Radiopharmaceuticals Market End User Analysis by Region, 2016-2028 (US$ Billion)
10.1. Hospitals Market Analysis 2016-2028 (US$ Billion)
10.1.1. North America
10.1.2. Europe
10.1.3. Asia Pacific
10.1.4. Latin America
10.1.5. Middle East & Africa
10.2. Ambulatory Surgical Centers Market Analysis 2016-2028 (US$ Billion)
10.3. Diagnostic Centers Market Analysis 2016-2028 (US$ Billion)
10.4. Cancer Research Institutes Market Analysis 2016-2028 (US$ Billion)
11. Radiopharmaceuticals Market Analysis by Geography, 2016-2028 (US$ Billion)
11.1. North America Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.1.1. U.S. Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.1.1.1. Type
11.1.1.2. Application
11.1.1.3. Procedural Volume Assessment
11.1.1.4. Source
11.1.1.5. End User
11.1.2. Canada Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.1.3. Mexico Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.2. Europe Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.2.1. UK Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.2.1.1. Type
11.2.1.2. Application
11.2.1.3. Procedural Volume Assessment
11.2.1.4. Source
11.2.1.5. End User
11.2.2. France Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.2.3. Germany Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.2.4. Spain Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.2.5. Russia Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.2.6. Italy Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.2.7. Rest of Europe Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3. Asia Pacific Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3.1. China Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3.1.1. Type
11.3.1.2. Application
11.3.1.3. Procedural Volume Assessment
11.3.1.4. Source
11.3.1.5. End User
11.3.2. Japan Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3.3. South Korea Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3.4. India Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3.5. Australia Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3.6. Southeast Asia Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3.7. Taiwan Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.3.8. Rest of Asia Pacific Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.4. Latin America Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.4.1. Brazil Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.4.1.1. Type
11.4.1.2. Application
11.4.1.3. Procedural Volume Assessment
11.4.1.4. Source
11.4.1.5. End User
11.4.2. Argentina Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.4.3. Rest of Latin America Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.5. Middle East Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.5.1. Israel Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.5.1.1. Type
11.5.1.2. Application
11.5.1.3. Procedural Volume Assessment
11.5.1.4. Source
11.5.1.5. End User
11.5.2. Turkey Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.5.3. Saudi Arabia Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.5.4. UAE Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.5.5. Rest of Middle East Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.6. Africa Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.6.1. Egypt Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.6.1.1. Type
11.6.1.2. Application
11.6.1.3. Procedural Volume Assessment
11.6.1.4. Source
11.6.1.5. End User
11.6.2. South Africa Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
11.6.3. Rest of Africa Radiopharmaceuticals Market Analysis 2016-2028 (US$ Billion)
12. Company Profiles
12.1. Cardinal Health
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Benchmarking
12.1.4. Strategic Initiatives
12.2. GE Healthcare
12.3. Curium
12.4. Lantheus Medical Imaging
12.5. Bayer AG
12.6. Bracco Imaging
12.7. Eczacýbaþý-Monrol Nuclear Products
12.8. Nordion
12.9. Advanced Accelerator Applications
12.10. NTP Radioisotopes
12.11. JSC Isotope
12.12. NorthStar Medical Radioisotopes
12.13. Eckert & Ziegler
12.14. Braun Melsungen AG
12.15. Smith & Nephew plc
12.16. Zimmer Biomet
12.17. Hanger Inc.
12.18. Otto Bock Healthcare GmBH.
13. COVID-19 Impact Analysis
13.1. Global Radiopharmaceuticals Market, 2020 – 2028, Pre-V/S Post COVID 19
13.2. Estimated Impact of The Coronavirus (Covid-19) Epidemic on the Radiopharmaceuticals Market Size In 2022, By Scenario
13.3. Impact on Supply Chain and Production in Radiopharmaceuticals Market
13.4. Impact on Import and Export
14. Import-Export Analysis
14.1. North America Radiopharmaceuticals Import-Export, 2016 – 2021
14.2. Europe Radiopharmaceuticals Import-Export, 2016 – 2021
14.3. Asia Pacific Radiopharmaceuticals Import-Export, 2016 – 2021
14.4. Latin America Radiopharmaceuticals Import-Export, 2016 – 2021
14.5. Middle East America Radiopharmaceuticals Import-Export, 2016 – 2021
14.6. Africa Radiopharmaceuticals Import-Export, 2016 – 2021
15. Radiopharmaceuticals Marketing Channel Analysis
15.1. Marketing Channel
15.1.1. Direct Marketing
15.1.2. Indirect Marketing
15.1.3. Development Trend
15.2. Market Positioning
16. Radiopharmaceuticals Manufacturing Cost Analysis
16.1. Key Raw Materials
16.2. Key Raw Material Suppliers
16.3. Market Concentration Rate
16.4. Manufacturing Cost Structure
16.5. Process Analysis
17. Conclusion
Cardinal Health
GE Healthcare
Curium
Lantheus Medical Imaging
Bayer AG
Bracco Imaging
Eczacýbaþý-Monrol Nuclear Products
Nordion
Advanced Accelerator Applications
NTP Radioisotopes
JSC Isotope
NorthStar Medical Radioisotopes
Eckert & Ziegler
Braun Melsungen AG
Smith & Nephew plc
Zimmer Biomet
Hanger Inc.
Otto Bock Healthcare GmBH.
Radiopharmaceuticals Market by Type
Diagnostic Nuclear Medicine
Therapeutic Nuclear Medicine
Radiopharmaceuticals Market by Application
Diagnostic Applications
Therapeutic Applications
Radiopharmaceuticals Market by Procedural Volume Assessment
Diagnostic Procedures
Therapeutic Procedures
Radiopharmaceuticals Market by Source
Nuclear Reactors
Cyclotrons
Radiopharmaceuticals Market by End User
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Cancer Research Institutes
Others
Methodology
Qualitative Analysis:
Industry Status and Trends
Market segment by regions, types, applications, and forecast
Market opportunities, potential, government policies, and influence factors.
Quantitative Analysis:
Market size (value, historical data, and forecast (2017-2030)
Market size by types, regions, and applications, from 2017 to 2030.
Market forecast based on the potential demand from downstream clients/buyers, government, influence factors, and the total economic indication, maybe occur in the following years.
Research Data Source:
Secondary Data
Secondary sources incorporate yearly reports, press releases, and investor presentations of companies; Journal of Science, authorised statistical yearbook, National Customs, Industry Association; Secondary research has mostly been functional to obtain key information about the industry’s supply chain, the market downstream buyers, technical dynamics development trends, the main vendors of this market, and market classification & segmentation according to the industry trends, regional markets, and key developments from a market and business oriented viewpoint.
Key Data from Secondary
Items
Source
Market Size (Value & Volume)
Industry Association
Magazines
Journals
Press Releases
Statistical Yearbook
National Customs
Revenue of Companies
Paid Databases
Data Centre
Annual Reports
Hoover
Public Databases
Bloomberg Business
Qualitative Analysis
Company Annual Reports
Press Releases
Industry Associations
Primary Data
In the primary research procedure, various sources from both the Sales and consumption sides were interviewed to acquire qualitative and quantitative information for this report. The primary sources from the Sales side include key product manufacturers (and their competitors), industry experts, industry association, research institutions, distributors, dealers, and traders, as well as the raw materials suppliers and producers, etc. The primary sources from the consumption side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and associated key executives from various key companies and organizations functioning in the global market. Primary research was led to identify segmentation types, product price range, product applications, key players, raw materials supply and downstream consumption, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Data from Primary
Items
PARAMETER
KEY DATA
Market Segmented by Regions
Total Market Size and Regional Market Status Growth Rate Forecast from 2022-2030
Major Regions: North Americas, Europe, Asia Pacific, Middle East and Africa, South Americas, etc. Market Status and Forecast
Submarket by Types
Historical (2017-2021) and Forecast (2022-2030) Data
Value and Growth Rate of Different Downstream Applications
Submarket by Applications
Historical (2017-2021) and Forecast (2022-2030) Data
Company Annual Reports Press Releases Industry Associations
Market Size Estimation
The top-down and bottom-up methods have been employed to estimate and forecast the market size in each region, different types, and applications. The most important vendors in the market have been discovered through secondary research and their market shares in the individual regions were determined through primary and secondary research.
Key players in the market are identified through secondary research and their market incomes are determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top manufacturers, whereas primary research included extensive interviews of key opinion leaders and industry specialists such as knowledgeable front-line staff, directors, CEOs, and marketing executives. The percentage splits, market shares, growth rate, and breakdowns of the product markets are determined by using secondary sources and confirmed through primary sources.
All percentage shares split, and breakdowns have been determined using secondary sources and validated through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, examined in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Frequently Asked Questions
Which key factors will influence radiopharmaceuticals market growth over 2022-2028?
The increased incidence of malignant diseases brought on by an aging population and unhealthful eating habits are the leading causes of the expanding use of radiopharmaceuticals.
What will be the value of the radiopharmaceuticals market during 2022-2028?
According to Beyond Market Insights, the global radiopharmaceuticals market size was worth USD 4.6 billion in 2021 and is estimated to grow to USD 8.3 billion by 2028, with a compound annual growth rate (CAGR) of approximately 8.80 percent over the forecast period.
Which region will contribute notably toward the radiopharmaceuticals market value?
In 2021, North America dominated radiopharmaceuticals because of the region’s robust healthcare infrastructure.
Which are the significant players leveraging the radiopharmaceuticals market growth?
Some of the main competitors dominating the global radiopharmaceuticals market include – Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG, Bracco Imaging, Eczacýbaþý-Monrol Nuclear Products, Nordion, Advanced Accelerator Applications, NTP Radioisotopes, JSC Isotope, NorthStar Medical Radioisotopes, Eckert & Ziegler, Braun Melsungen AG, Smith & Nephew plc, Zimmer Biomet, Hanger Inc., and Otto Bock Healthcare GmBH.
